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Abstract
Intellectual disability and seizures are frequently associated with hypomagnesemia and have an important genetic
component. However, to find the genetic origin of intellectual disability and seizures often remains challenging because of
considerable genetic heterogeneity and clinical variability. In this study, we have identified new mutations in CNNM2 in five
families suffering from mental retardation, seizures, and hypomagnesemia. For the first time, a recessive mode of
inheritance of CNNM2 mutations was observed. Importantly, patients with recessive CNNM2 mutations suffer from brain
malformations and severe intellectual disability. Additionally, three patients with moderate mental disability were shown to
carry de novo heterozygous missense mutations in the CNNM2 gene. To elucidate the physiological role of CNNM2 and
explain the pathomechanisms of disease, we studied CNNM2 function combining in vitro activity assays and the zebrafish
knockdown model system. Using stable Mg2+ isotopes, we demonstrated that CNNM2 increases cellular Mg2+ uptake in
HEK293 cells and that this process occurs through regulation of the Mg2+-permeable cation channel TRPM7. In contrast,
cells expressing mutated CNNM2 proteins did not show increased Mg2+ uptake. Knockdown of cnnm2 isoforms in zebrafish
resulted in disturbed brain development including neurodevelopmental impairments such as increased embryonic
spontaneous contractions and weak touch-evoked escape behaviour, and reduced body Mg content, indicative of impaired
renal Mg2+ absorption. These phenotypes were rescued by injection of mammalian wild-type Cnnm2 cRNA, whereas
mammalian mutant Cnnm2 cRNA did not improve the zebrafish knockdown phenotypes. We therefore concluded that
CNNM2 is fundamental for brain development, neurological functioning and Mg2+ homeostasis. By establishing the loss-of-
function zebrafish model for CNNM2 genetic disease, we provide a unique system for testing therapeutic drugs targeting
CNNM2 and for monitoring their effects on the brain and kidney phenotype.
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Introduction
Brain defects including seizures, migraine, depression and
intellectual disability are frequently associated with hypomagne-
semia [1]. Indeed, low Mg2+ concentrations may cause epilep-
tiform activity during development [2]. Specifically, the Mg2+
channel transient receptor potential melastatin 7 (TRPM7) is
essential for brain function and development [3]. Interestingly,
patients with genetic defects in TRPM6, a close homologue of
TRPM7, may have neurological complications [4]. Although
TRPM6 and TRPM7 share similar Mg2+ transporting properties,
they are differentially expressed and regulated [5]. TRPM7 is a
ubiquitously expressed protein regulating intracellular Mg2+
levels in a broad range of cells, whereas TRPM6 is localized in
the luminal membrane of renal and intestinal epithelia involved
in Mg2+ absorption [1,6–8]. Recently, we have identified
mutations in the gene encoding cyclin M2 (CNNM2) in two
unrelated families with dominant isolated hypomagnesemia
(CNNM2 [MIM 607803]) [9]. Patients suffered from symptoms
associated with low serum Mg2+ levels (0.3–0.5 mM) such as
tremors, headaches and muscle weakness. The role of CNNM2 in
the kidney for the maintenance of serum Mg2+ levels can be
traced to the distal convoluted tubule (DCT), where also TRPM6
is expressed. Here, CNNM2 is present in the basolateral
membrane of DCT cells and its expression is regulated by
dietary Mg2+ availability [9–10].
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Although CNNM2 has been proposed as a Mg2+ transporter in
overexpression studies in Xenopus oocytes [11], Mg2+ transport
could not be directly measured in mammalian cells using patch
clamp analysis [9]. On the other hand, modelling of the CNNM2
cystathionine b-synthase (CBS) domain resulted in the identifica-
tion of a Mg2+-ATP binding site, suggesting a role in Mg2+ sensing
within the cell [12]. Consequently, the molecular mechanism
explaining the role of CNNM2 in DCT-mediated Mg2+ transport
remains to be elucidated.
The CNNM2 gene is ubiquitously expressed in mammalian
tissues, most prominently in kidney, brain and lung [12–13].
Although the role of CNNM2 beyond the kidney has never been
studied, genome wide association studies have related the CNNM2
locus to blood pressure, coronary artery disease and schizophrenia,
suggesting an important role of CNNM2 in the cardiovascular
system and brain [14–15]. CNNM2 is widely conserved among
species. In zebrafish (Danio rerio), a frequently used model for ion
homeostasis and human genetic diseases in general [16–17], the
cnnm2 gene is duplicated and two paralogues, cnnm2a and cnnm2b,
are described [18]. Both paralogues share a high conservation with
human CNNM2 (79% amino acid identity). In detail, transcripts
are abundantly expressed in zebrafish brain and in ionoregulatory
organs such as kidney and gills, which act as a pseudokidney in fish
[18]. Consistent with the regulation of CNNM2 transcripts in
mammals [11], the expression of cnnm2a and cnnm2b is regulated
by Mg2+ in vivo [18].
In the present study, we aim to elucidate the function of
CNNM2 in brain and kidney. Hence, we can demonstrate the
genetic origin of symptoms in five unrelated families suffering from
a distinct phenotype of mental retardation, seizures and hypo-
magnesemia, where we have identified novel mutations in the
CNNM2 gene. By combining functional analyses and a loss-of-
function approach in the zebrafish model, we provide functional
evidence for a key role of CNNM2 in brain development,
neurological activity and renal Mg2+ handling.
Results
Patients
Patients F1.1 and F1.2 presented in the neonatal period with
cerebral convulsions. Serum Mg2+ levels at manifestation were
found to be 0.5 mM in both patients (Table 1). Convulsions were
refractory to conventional antiepileptic medications. Intravenous
Mg2+ supplementation with ,1 mmol/kg body weight/day was
initiated after oral Mg2+ failed to correct serum Mg2+ levels.
However, seizure activity continued even in face of normomagne-
semia. An extensive analysis for infectious causes or inborn errors
of metabolism did not yield any positive results. Ultrasound
examination of the kidneys did not reveal nephrocalcinosis,
whereas basal ganglia calcifications were noted in early central
nervous system (CNS) sonographies. During follow-up, severe
developmental delay was noted accompanied by microcephaly
(head circumference below third percentile for age and sex in both
patients). A magnetic resonance imaging (MRI) at 5.5 years of age
in patient F1.1 showed wide supratentorial outer cerebrospinal
liquor spaces with failure of opercularization together with a
significantly reduced myelinization of the white matter tract
(Figure 1C–D). The severe degree of intellectual disability, which
became apparent with increasing age comprised major deficits in
cognitive function, the inability to verbally communicate, and
severely limited motor skills. Both children are not able to perform
main activities of daily living and require full-time care by an
attendant. Seizure activity is sufficiently controlled in the older
brother by valproate and lamotrigine, electroencephalography
(EEGs) merely shows generalized slowing, but no epileptic activity.
In contrast, the younger sister suffers from ongoing generalized,
myoclonic seizures despite antiepileptic treatment with valproate
and levetiracetame. Laboratory investigations during follow-up
demonstrated persistent hypomagnesemia of ,0.6 mM despite
oral Mg2+ supplementation.
Patients F2.1, F3.1, and F4.1 presented with seizures during
infancy (between 4 and 12 months of age). Laboratory evaluation
yielded isolated hypomagnesemia of ,0.5 mM (Table 1). Urine
analyses demonstrated inappropriate fractional excretion for Mg2+
in face of persistent hypomagnesemia. In addition, the renal Mg2+
leak was verified by Mg2+ loading tests in patients F2.1 and F4.1 as
described before [19]. Urinary calcium excretion rates were
normal, renal ultrasound excluded the presence of nephrocalci-
nosis. After acute therapy with intravenous Mg2+, the patients
received a continuous oral Mg2+ supplementation of 0.5 to
1 mmol/kg body weight/day of elemental Mg2+. This oral therapy
however failed to correct the hypomagnesemia, serum Mg2+
remained in the subnormal range in all three children. Because of
recurrent cerebral seizures, patients F2.1 to F4.1 received diverse
antiepileptic medications. Currently only patient F4.1 is still
treated with clobazam.
In all three patients (F2.1 to F4.1), a significant degree of
intellectual disability was already noted in early childhood with
delayed speech development, but also impaired motor as well as
cognitive skills. In addition, patient F4.1 was noted to exhibit
disturbed social interaction, abnormal verbal and non-verbal
communication, as well as stereotyped behaviour and finally
received the formal diagnosis of early onset autism. All three
patients F2.1 to F4.1 were not able to attend regular schools.
Standardized intelligence testing in patients F2.1 and F3.1
revealed a significant degree of mental retardation (see Table 1).
While patients F2.1 and F3.1 are currently living with their
parents, patient F4.1 is placed in a home for children with mental
illness because of episodes of violence and destructive behaviour.
Author Summary
Mental retardation affects 1–3% of the population and has
a strong genetic etiology. Consequently, early identifica-
tion of the genetic causes of mental retardation is of
significant importance in the diagnosis of the disease, as
predictor of the progress of the disease and for the
determination of treatment. In this study, we identify
mutations in the gene encoding for cyclin M2 (CNNM2)
to be causative for mental retardation and seizures in
patients with hypomagnesemia. Particularly, in patients
with a recessive mode of inheritance, the intellectual
disability caused by dysfunctional CNNM2 is dramatically
severe and is accompanied by severely limited motor skills
and brain malformations suggestive of impaired early
brain development. Although hypomagnesemia has been
associated to several neurological diseases, Mg2+ status is
not regularly assessed in patients with seizures and mental
disability. Our findings establish CNNM2 as an important
protein for renal magnesium handling, brain development
and neurological functioning, thus explaining the physiol-
ogy of human disease caused by (dysfunctional) mutations
in CNNM2. CNNM2 mutations should be taken into
account in patients with seizures and mental disability,
specifically in combination with hypomagnesemia.
CNNM2 Mutations Impair Brain and Kidney Function
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Figure 1. Pedigrees and magnetic resonance imaging (MRI) studies of families with primary hypomagnesemia. (A) Pedigrees of
families F1–F5. Filled symbols represent affected individuals, mutant alleles are indicated by a minus (2) and plus (+) sign, respectively. (B)
Localization of the mutations in the CNNM2 protein structure (Uniprot Q9H8M5). CNNM2 contains a long signal peptide (64 amino acids) that is
cleaved at the membrane of the endoplasmic reticulum. The remaining part of the CNNM2 protein is trafficked to the plasma membrane, where it
becomes functionally active. White dots show the locations of the mutations. (C–D) MRI of the brain of patient F1.1 (C, T2 weighed images) and
CNNM2 Mutations Impair Brain and Kidney Function
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The parents of all three children (F2.1–F4.1) had normal serum
Mg2+ levels and no signs of intellectual disability.
Finally, patient F5.1 presented with muscle spasms and
dysesthesia in adolescence. Serum Mg2+ levels were found to be
low (,0.6 mM). Because of concomitant borderline hypokalemia,
she was suspected to have Gitelman syndrome ([MIM 263800])
and received oral Mg2+ and K+ supplements. Also this patient
exhibited a mild degree of intellectual disability. Unfortunately,
she was not available for further examination.
CNNM2 mutations in patients with mental retardation
Common genetic causes of mental retardation were excluded in
patients F1.1 and F2.1 by array CGH (comparative genomic
hybridization). The presence of two affected siblings together with
the suspected parental consanguinity in family F1 suggested an
autosomal-recessive pattern of inheritance. Therefore, we subject-
ed patients F1.1 and F1.2 to homozygosity mapping which, at a
cut-off size of .1.7 megabases (Mb), yielded eleven critical
intervals on autosomes with a cumulative size of 62 Mb. The gene
list generated from these loci included 322 RefSeq genes and
putative transcripts. CNNM2 in a critical interval of 7.1 Mb on
chromosome 10 emerged as the most promising candidate gene
because of its known role in Mg2+ metabolism [9,11–12,20].
Conventional Sanger sequencing of the complete coding region of
the CNNM2 gene revealed a homozygous mutation, c.364G.A,
leading to a non-conservative amino acid substitution of glutamate
to lysine at position 122 of the CNNM2 protein (p.Glu122Lys,
Figure 1A–B). The mutation was present in heterozygous state in
both parents. After discovery of this homozygous mutation in
patients F1.1 and F1.2, a larger cohort (n = 34) of patients with
Mg2+ deficiency of unknown origin was screened for mutations in
the CNNM2 gene. Mutations in heterozygous state were discov-
ered in patients F2.1 to F5.1 (Table 1). However, sequencing of the
complete coding region and adjacent exon-intron boundaries did
not reveal a second pathogenic allele. Next, we examined the
CNNM2 gene in parents and unaffected siblings of families F2 to
F4. The mutations previously identified in our patients were not
detected in either of the parents pointing to de novo mutational
events. Interestingly, patients F2.1 and F4.1 exhibited the same
mutation, p.Glu357Lys (c.1069G.A), affecting a highly conserved
amino acid residue in the 2nd membrane-spanning domain of the
CNNM2 protein. Also the p.Ser269Trp (c.806C.G) mutation
detected in patient F3.1 affects a highly conserved residue located
in the 1st transmembrane domain. All three mutations were
patient F2.1 (D, T2 weighed images). Left: Coronal images demonstrating a defect in myelinization of U-fibers (arrows) in patient F1.1 in contrast to a
normal myelin pattern in patient F2.1. Center: Coronal T2 weighted images showing widened outer cerebrospinal liquor spaces (dashed arrows) and
lack of opercularization (solid arrows) in patient F1.1, whereas a regular brain volume and insular lobe is observed in patient F2.1. Right: Absence of
cerebellar structural abnormalities in patients F1.1 and F2.1 on axial T2 weighted images at the level of the trigeminal nerve.
doi:10.1371/journal.pgen.1004267.g001
Table 1. Clinical and biochemical data of patients.
Patient F1.1 F1.2 F2.1 F3.1 F4.1 F5.1
Gender Male Female Female Female Male Female
Ethnicity Serbian Serbian German German German Polish
Age at manifestation 1 day 6 days 7 months 1 years 4 months 16 years
Follow-up 12 years 8 years 12 years 20 years 12 years None
Symptoms at
manifestation
Seizures Seizures Seizures Seizures,
Paresthesia
Seizures Myoclonus,
Paresthesia
Treatment Valproate,
Lamotrigine
Valproate,
Levetiracetame
Phenobarbital Valproate Clobazam Unknown
Neuroimaging Myelinization
defects,
Opercularization
defect, Widened
outer cerebrospinal
liquor spaces
Normal Normal Normal Unknown
Mental retardation Severe Severe Moderate Moderate Moderate Mild
Cognitive function IQ 55–57 IQ 55–59 Autism Unknown
Speech/Communication No verbal
speech, Limited
communication skills
No verbal
speech, Limited
communication skills
Expressive
language
disorder
Expressive
language
disorder
Limited
speech and
vocabulary
Unknown
Additional symptoms Very limited
motor skills
Very limited
motor skills
Impaired
motor skills,
severe obesity
Impaired
motor skills,
severe obesity
Impaired
motor skills
Unknown
Initial serum Mg2+ (mmol/L) 0.5 0.5 0.56 0.44 0.5 0.66
Follow-up serum Mg2+ (mmol/L) 0.66 0.54 0.56 0.53 0.68 -
Mutation (DNA level) c.364G.A c.364G.A c.1069G.A c.806C.G c.1069G.A c.988C.T
Mutation (Protein level) p.Glu122Lys p.Glu122Lys p.Glu357Lys p.Ser269Trp p.Glu357Lys p.Leu330Phe
Zygosity Homozygous Homozygous Heterozygous Heterozygous Heterozygous Heterozygous
doi:10.1371/journal.pgen.1004267.t001
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ranked ‘‘probably damaging’’ by Polyphen-2 when tested for
functional consequences of the mutations (p.Glu122Lys,
p.Ser269Trp and p.Glu357Lys with scores of 0.981, 1.000 and
1.000, respectively). Finally, in patient F5.1 with a late manifes-
tation and putatively milder phenotype, the variant p.Leu330Phe
(c.988C.T) was identified in heterozygous state. This variant
affects an amino acid residue conserved among mammals,
however a phenylalanine appears at this position in certain fish
species. The variant is predicted to be possibly damaging by
Polyphen-2 with a score of 0.711. None of the identified variants
was detected in 204 controls or present in publically available
exome data.
CNNM2 increases Mg2+ transport
To clarify the function of CNNM2, Human Embryonic Kidney
(HEK293) cells were transiently transfected with mouse Cnnm2 or
mock constructs and examined for Mg2+ transport capacity using
the stable 25Mg2+ isotope. At baseline, approximately 10% of the
total intracellular Mg2+ content consists of 25Mg2+, which is the
natural abundance of 25Mg2+ [21]. By incubating the cells in a
physiological buffer containing pure 25Mg2+, the intracellular
25Mg2+ concentration increases over time. Interestingly, Cnnm2
expressing cells displayed a higher 25Mg2+ uptake compared to
mock cells (Figure 2A). After 5 minutes, Cnnm2-expressing cells
had approximately 2 times more 25Mg2+ uptake than mock-
transfected cells (Figure 2B). All further experiments were
performed at the 5 minutes time point to cover the exponential
phase of the uptake. To reduce the background in 25Mg2+ uptake,
inhibitors of known Mg2+ channels and transporters were added
during the uptake process; 2-APB to inhibit TRPM7 [22],
Ouabain to block the Na+-K+-ATPase [23], Quinidin for
SLC41A1 [24] and Nitrendipin [25] for silencing MagT1 activity
(Figure 2C). Only 2-APB was capable of significantly inhibiting
25Mg2+ uptake in HEK293 cells. Moreover, 2-APB inhibition also
abolished the CNNM2-dependent increase in 25Mg2+ uptake.
Dose-response experiments confirmed that the IC50 of 2-APB
inhibition is 22 mM (Figure 2D). CNNM2-dependent 25Mg2+
uptake was found to be independent of Na+ and Cl2 availability,
when uptakes were performed in N-methyl-d-glucamine (NMDG)
or Gluconate buffers (Figure 2E). Interestingly, the highest
CNNM2-dependent 25Mg2+ uptake was measured between 1–
2 mM, suggesting a Km in the physiological range of approx-
imately 0.5 mM (Figure 2F). At high Mg2+ concentrations (5 mM),
25Mg2+ uptake was inhibited. When subjected to 24 hours 25Mg2+
loading, Cnnm2-expressing cells showed a significantly higher
25Mg2+ content baseline. Subsequently, 15 minutes extrusion of
Cnnm2-expressing cells demonstrated no difference in Mg2+
extrusion rate, compared to mock-transfected cells (Figure 2G).
Mutations impair CNNM2-dependent Mg2+ uptake
To characterize the effect of the CNNM2 mutations identified in
our hypomagnesemic patients, 25Mg2+ uptake was determined in
HEK293 cells expressing mutant CNNM2 proteins. Of all
missense mutations that are identified to date, only p.Leu330Phe
was capable of increasing 25Mg2+ uptake to a similar extent as
wild-type CNNM2 (Figure 3A). All other CNNM2 mutants
exhibited severely decreased 25Mg2+ uptake or had lost their
ability to increase 25Mg2+ uptake completely. To examine whether
CNNM2 dysfunction can be explained by a reduced plasma
membrane expression, all mutants were subjected to cell surface
biotinylation analysis. Indeed, p.Glu122Lys CNNM2 membrane
expression was significantly reduced compared with wild-type
CNNM2 (66% decrease, P,0.05) and p.Ser269Trp CNNM2
showed a trend towards reduction (46% decrease, Figure 3B).
Disturbed Mg2+ homeostasis and brain abnormalities in
cnnm2 morphant zebrafish larvae
Patients with mutations in CNNM2 suffer from hypomagnese-
mia. Therefore, zebrafish cnnm2 morphants were tested for
disruptions of their Mg2+ homeostasis. Extraction of serum from
zebrafish embryos is technically not feasible. Thus, total body Mg
contents of controls and morphant larvae were examined at 5 days
post-fertilization (dpf). During these 5 days of zebrafish develop-
ment, intestinal absorption of Mg2+ does not take place since
larvae do not eat and drink. For that reason, Mg2+ homeostasis is
the result of the balance between Mg2+ excretion, passive Mg2+
uptake from the yolk, Mg2+ reabsorption in the kidney, and Mg2+
uptake in the integument, where ionocytes are analogous to renal
tubular cells in terms of function and transporter and channel
expression [16]. Therefore, when knocking down a gene involved
in active epithelial Mg2+ uptake, disturbances in total body Mg
content reliably represent disturbances in active Mg2+ reabsorp-
tion and/or uptake, through pronephric (renal) tubular cells and/
or their analogous in the skin, respectively.
The cnnm2a gene, one of the two zebrafish cnnm2 paralogues, is
expressed during early development (Figure 4A). Injection in
embryos of higher doses than 2 ng of morpholino (MO) blocking
cnnm2a translation resulted in a significantly reduced survival
compared to controls at 5 dpf (Figure 4B). At non-lethal doses of
MO (when mortality caused by the cnnm2a-MO does not differ
significantly from mortality in controls), knockdown of cnnm2a
resulted in morphological phenotypes characterized by enlarged
pericardial cavities and notochord defects (Figure 4C–D). The
biochemical equivalency between mammalian CNNM2 and its
zebrafish orthologue cnnm2a was demonstrated by the fact that co-
injection of cnnm2a-MO with mouse wild-type Cnnm2 cRNA
induced a rescue of all phenotypes observed (Fig. 4E). Conversely,
co-injection with mouse mutant Cnnm2 cRNA did not result in any
rescue. In line with the symptom of hypomagnesemia in patients
with mutated CNNM2, cnnm2a morphants exhibited significantly
reduced levels of Mg compared to controls when increasing doses
of MO were injected (Figure 4F). Total Mg content in cnnm2a
morphants was restored to control levels when cnnm2a-MO was co-
injected with cRNA encoding for mouse wild-type CNNM2 and
not with mutant Cnnm2 (Figure 4G). This demonstrated that the
defects observed in morphants were indeed caused by dysfunc-
tional cnnm2a and not by toxic off-target effects.
Zebrafish cnnm2b is also expressed during early development
(Figure 5A). Survival in cnnm2b morphants was not affected by the
knockdown (Figure 5B). The cnnm2b morphants were character-
ized by enlarged pericardial cavities, kidney cysts and, in
agreement with the morphological brain abnormalities observed
in the F1.1 patient, by accumulation of cerebrospinal fluid in the
cerebrum (Figure 5C–D). Interestingly, most cnnm2b morphants
were morphologically normal at the dose of 2 ng MO/embryo
(Figure 5D). All morphological phenotypes were rescued by co-
injection of cnnm2b-MO with mouse wild-type Cnnm2 (Figure 5E).
As for cnnm2a, cnnm2b was demonstrated to reduce Mg levels when
knocked down (Figure 5F) and to be functionally equivalent to
mammalian CNNM2 in cRNA rescue experiments (Figure 5G).
Phenotype rescue with mouse wild-type Cnnm2 demonstrated the
absence of toxic off-target effects and the specificity of the cnnm2b-
MO to produce defects attributable to impaired CNNM2 function.
Brain abnormalities and increased spontaneous
contractions in cnnm2 morphant zebrafish embryos
Patients with CNNM2 mutations suffer from mental retardation
and seizures. As the severe neurological phenotype in patients F1.1
CNNM2 Mutations Impair Brain and Kidney Function
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Figure 2. CNNM2 increases Mg2+ uptake in HEK293 cells. (A) Time curve of 25Mg2+ uptake in mock (circles) and CNNM2 (squares) transfected
cells. (B) Representation of the normalized Mg2+ uptake after 5 minutes. (C) 25Mg2+ uptake in the presence of inhibitors of ion transporters, black bars
represent mock cells and white bars represent CNNM2-transfected cells. (D) Dose-response curve of 25Mg2+ transport inhibition by 2-APB in mock
CNNM2 Mutations Impair Brain and Kidney Function
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and F1.2 was diagnosed early after birth (Table 1), we
hypothesized that the deleterious effects of mutant CNNM2 could
result from early developmental defects in brain primordia. In
zebrafish, the segmental organization of the brain rudiment, and
morphologically visible boundaries and primordia are established
at 25 hours post-fertilization (hpf). At this stage, maldevelopment
of the midbrain hindbrain boundary (MHB) is observed in cnnm2a
morphant embryos (Figure 6A–B). Interestingly, these phenotypes
could not be rescued by exposure to media with high Mg2+
concentrations (Figure 6B), even though these media significantly
increased the Mg content of morphant embryos (Figure 6C). More
importantly, phenotypes were rescued by co-injection with the
mouse orthologue cRNA and not by co-injection with the mutant
transcript (Figure 6D). In addition to brain developmental defects,
the frequency of spontaneous embryonic contractions was increased
in cnnm2amorphants compared to controls (Figure 6E), which could
indicate that (motor) neurons are hyperexcitable [26]. This
phenotype was not rescued by exposure to high Mg2+ concentra-
tions in the medium (Figure 6E). In contrast, co-injection of the
cnnm2a-MO with mouse wild-type Cnnm2 cRNA did result in a
rescue of the neurological functioning (Figure 6F). Conspicuously,
co-injection with the mutant Cnnm2 cRNA even worsened this
motor neuronal phenotype by increasing the number of spontane-
ous contractions significantly compared to embryos injected only
with cnnm2a-MO (Figure 6F; Movies S1, S2, S3).
In the case of cnnm2b morphants, enlarged tectums were also
present in a 30% of morphants in addition to the defects in the
MHB, phenotypes that were not rescued by exposure to high Mg2+
concentrations (Figure 7A–C) but by co-injection of cnnm2b-MO
with mouse wild-type Cnnm2 cRNA (Figure 7D). Spontaneous
contraction frequency was increased in cnnm2b morphants
(Figure 7E), restored to control levels with overexpression of mouse
wild-type Cnnm2 (Figure 7F), and 4-fold increased with overexpres-
sion of mouse mutant Cnnm2 compared to cnnm2b morphants
injected solely with cnnm2b-MO (Figure 7F; Movies S4, S5, S6).
The validated cRNA rescue controls proved the specificity of
the brain defects observed, attributable to dysfunctional ortholo-
gues of CNNM2 for both translation blocking MOs used.
Weaker touch-evoked escape behaviour in cnnm2
morphant zebrafish larvae
As our in vitro data pointed to a putative interaction between
CNNM2 and TRPM7 and zebrafish morphants presented brain
developmental defects, the touch-evoked escape behaviour in
zebrafish was evaluated, a parameter largely dependent on TRPM7
activity in sensory neurons and/or brain development [27–29].
Indeed, in cnnm2a and cnnm2b morphants (at 5 dpf), touch-evoked
escape behaviour was significantly weaker than that in controls
(Figures S1, S2). Additionally, this phenotype was rescued by co-
injection of the MOwith wild-type Cnnm2 cRNA and not by mutant
Cnnm2 cRNA. As for the other phenotypes, cRNA rescues proved
the causality between the weak touch-evoked escape behaviour in
morphants and dysfunctional cnnm2 paralogues.
Discussion
In the present study, a severe brain phenotype consisting of
cerebral seizures, mental retardation and brain malformations in
patients with hypomagnesemia was shown to be caused by
mutations in CNNM2. Our experiments established CNNM2 as a
new essential gene in brain development, neurological functioning
and Mg2+ homeostasis. This notion is supported by the following
observations; i) hypomagnesemic patients with CNNM2 mutations
suffer from seizures, mental disability, and if mutations are present
in recessive state, brain malformations are observed in addition; ii)
Mg2+ supplementation does not improve the neurological pheno-
type of the patients; iii) CNNM2 increases Mg2+ uptake in
HEK293 cells, whereas mutant CNNM2 does not; iv) knockdown
of CNNM2 orthologues in zebrafish results in impaired develop-
ment of the brain, abnormal neurodevelopmental phenotypes
manifested as altered locomotor and touch-evoke escape behav-
iours, and Mg wasting; v) the zebrafish phenotype can be rescued
by injection of mouse Cnnm2 cRNA.
In addition to the previously reported dominant mode of
inheritance [9], the genetic findings in our patients support
heterogenous patterns of inheritance. In family F1, a recessive
mode of CNNM2 inheritance was observed. The homozygous
CNNM2 p.Glu122Lys mutation in this family resulted in the
manifestation of a neonatal onset and a considerably more severe
cerebral involvement than in the remaining patients. Yet, a central
nervous system (CNS) phenotype with seizures and intellectual
disability, which was not reported previously, represented the
cardinal clinical symptom in all of our patients. Seizures
constituted the major symptom at manifestation coinciding with
hypomagnesemia, but were also seen during follow-up despite
Mg2+ supplementation. Pronounced Mg2+ deficiency reflected by
severely low serum Mg2+ levels clearly represents a promotive
element in the development of seizures. However, the persistence
of seizure activity despite Mg2+ supplementation might point to a
genuine disturbance in brain function caused by defective
CNNM2. Accordingly, the extent of hypomagnesemia found in
the two siblings with the recessive mutation, F1.1 and F1.2, was
identical to other patients (F2.1–F5.1) with heterozygous CNNM2
mutations and a milder neurological phenotype. Continuous oral
Mg2+ supplementation stabilized serum Mg2+ levels in the
subnormal range, however a complete normalization of Mg2+
metabolism could not be achieved in any of the patients.
In three out of five families (F2, F3 and F4), the mutation of the
patient was not present in the parents. This finding supports the
recent advancements evidencing that de novo mutations provide an
important mechanism in the development of mental disability
disorders [30]. Remarkably, the same de novo p.Glu357Lys
mutation was identified in two unrelated individuals. Although
the mutation rate along the human genome varies significantly
[31], the chance to observe an identical de novo base pair change in
two individuals is extremely small, supporting causality of this
mutation. The clinical and genetic findings observed in patient
F5.1 should be interpreted with caution. Though the p.Leu330Phe
variant was not present in controls or exome variant databases, the
presence of an innocuous polymorphism cannot be completely
excluded. The clinical phenotype with a milder degree of
intellectual disability and a later manifestation with hypomagne-
semic symptoms during adolescence support a partial loss of
CNNM2 function caused by the p.Leu330Phe variant. Unfortu-
nately, the patient was not available for clinical re-evaluation.
(circles) and CNNM2 (squares) transfected cells. (E) The effect of Na+ and Cl2 availability on 25Mg2+ uptake in mock (black bars) and CNNM2 (white
bars) transfected cells. (F) 25Mg2+ uptake as a function of extracellular 25Mg2+ availability in mock (circles) and CNNM2 (squares) transfected cells. (G)
25Mg2+ extrusion in mock (circles) and CNNM2 (squares) transfected cells. Each data point represent the mean of 3 independent experiments 6 SEM.
* indicates significant differences compared to mock (P,0.05).
doi:10.1371/journal.pgen.1004267.g002
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Figure 3. CNNM2 mutations impair Mg2+ uptake in HEK293 cells. (A) Time curve of 25Mg2+ uptake in mock, wild-type CNNM2 and mutant
CNNM2 transfected cells. Symbols indicate cells transfected with the vector empty (N mock) or containing Cnnm2 sequences encoding for wild-type
or mutant CNNM2 proteins (& CNNM2, m CNNM2-p.Glu122Lys, . CNNM2-p.Ser269Trp, X CNNM2-p.Leu330Phe, # CNNM2-p.Glu357Lys, %
CNNM2-p.Thr568Ile). Each data point represent the mean of 3 independent experiments6 SEM. * indicates significant differences compared to mock
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Over the recent years, the function of CNNM2 in the context of
Mg2+ handling has been heavily debated [9,11–13,20]. Therefore,
an important question is how CNNM2 mutations cause impaired
Mg2+ metabolism and lead to CNS dysfunction. Functional studies
in HEK293 cells demonstrated a putative role in cellular Mg2+
transport. Overexpression of CNNM2 increased cellular Mg2+
uptake, which was abrogated by introduction of the CNNM2
mutants identified in our patients. The p.Ser269Trp and
p.Glu357Lys mutants as well as the previously published
p.Thr568Ile mutant [9], all identified in heterozygous state, failed
to enhance the cellular Mg2+ uptake, indicating a loss-of-function
in mutated CNNM2. The recessively inherited p.Glu122Lys
mutant identified in patients F1.1 and F1.2 displayed a small but
significant residual function, while Mg2+ uptake was almost
completely retained for mutant p.Leu330Phe. Biotinylation
experiments demonstrated a trafficking defect of p.Glu122Lys
and p.Ser269Trp mutants supporting a loss-of-function nature of
CNNM2 mutations. Together, these findings argue for distinct
degrees of severity of the disease depending on the number of
affected alleles. Furthermore, a small residual function of
p.Glu122Lys is in line with the lack of a clinical phenotype in
the parents of family F1. The parents, however, declined a
thorough evaluation of their Mg2+ status.
To further analyze the relevance of CNNM2 for brain and
Mg2+ metabolism deduced from the human disease model, the
translation of orthologues of CNNM2 (cnnm2a and cnnm2b) was
knocked down in zebrafish. In line with the human disease, the
concentration of total body Mg was decreased in zebrafish cnnm2a
and cnnm2b morphants when compared to controls. The decrease
in total body Mg content is interpreted as a decrease in the renal
absorption and/or skin uptake (through ionocytes analogous to
renal tubular cells) of the ionic fraction, Mg2+, since only Mg2+ is
transported transcellularly and no intestinal Mg2+ uptake takes
place in zebrafish larvae. Additionally, Mg losses observed in
morphant larvae were rescued by expression of wild-type Cnnm2,
but not by expression of mutant Cnnm2. This demonstrates the
specificity of our MO antisense oligos, as well as the functional
equivalence between mammalian CNNM2 and its zebrafish
orthologues.
Consistent with the human pathology, knockdown of cnnm2a or
cnnm2b induced brain malformations. Specifically, the brain
phenotype observed in cnnm2b morphants resembles that found
in patient F1.1 showing enlarged outer cerebrospinal liquor
spaces. This provides further consistency to link CNNM2
dysfunction with the brain morphological defects found in this
homozygous patient. The absence of outer cerebrospinal liquor
spaces in the cerebrum of cnnm2a morphants shows that cnnm2
paralogues in zebrafish are a case of subfunctionalization at the
level of the cerebrum. CNS malformations were rescued in
morphants by co-injection with mouse wild-type Cnnm2.
In homozygous patients, the neurological defects became
evident early after birth. In line with a developmental role for
CNNM2 within the CNS, gene expression of zebrafish cnnm2a and
cnnm2b peaked within the first 24 hpf. In addition, in situ
hybridization located cnnm2a expression specifically in the MHB
[32], an organizing center in the neural tube that determines
neural fate and differentiation in the CNS during development
[33–34]. Indeed, the most striking brain developmental defect in
our study is maldevelopment of the MHB. These defects were
rescued with Cnnm2 cRNA. Interestingly, the brain phenotypes
observed in both zebrafish and patients were independent of
Mg2+, as Mg2+ supplementation was unsuccessful to rescue the
phenotypes. Thus, our findings suggest that a brain-specific
CNNM2 function is crucial for the development of constitutive
regions of the CNS, which in the zebrafish model is illustrated by
defects in the MHB.
At 25 hpf, a time point in which the locomotor behaviour is
unaffected by the brain and only depends on signals from the
spinal cord [27], zebrafish morphant embryos displayed an
increased frequency of spontaneous contractions, especially when
the MOs were co-injected with mutant Cnnm2. This hyperexcit-
ability of motor neurons suggests a function of zebrafish Cnnm2
proteins in the regulation of the activity of the neurological
network in the spinal cord or in the synaptic junctions with muscle
fibbers. Consistent with these findings, patients with mutations in
CNNM2 presented impaired motor skills, which were severe in the
case of homozygous patients.
In the CNS, TRPM7 is essential during early development
[35], as it modulates neurotransmitter release in sensory neurons
[36–37]. Specifically, when using 2-APB, an inhibitor of TRPM7
[22], CNNM2-dependent Mg2+ transport was abolished in
HEK293 cells. Remarkably, in a similar fashion to trpm7 mutants
in zebrafish [28–29], cnnm2a or cnnm2b morphants showed weaker
touch-evoked escape behaviour compared to controls. In 5 dpf
larvae, and unlike in 25 hpf embryos, locomotor behaviours
elicited by touch require the involvement of high brain structures
[27]. Therefore, it is reasoned that CNNM2 conditions locomo-
tor behaviour with an etiology that can be related to lack of
excitation of sensory neurons via TRPM7 and/or to the defects in
early brain development observed in zebrafish morphant
embryos. In kidney, where CNNM2 is expressed at the
basolateral membrane in DCT, specific regulation of TRPM7
Mg2+ reabsorption is unlikely, since TRPM6 is the main Mg2+
transporter in this segment. TRPM7 is a ubiquitously expressed
gene regulating cellular Mg2+ metabolism, which is for instance
involved in regulation of brain Mg2+ levels [6]. Therefore, one
could hypothesize that CNNM2 may regulate other proteins in
addition to TRPM7 in kidney for the control of Mg2+
reabsorption, which remain to be identified.
In conclusion, our findings of CNNM2 mutations in patients
with hypomagnesemia and severe neurological impairment widen
the clinical spectrum of CNNM2-related disease. By establishing a
zebrafish CNNM2 loss-of-function model of the genetic disease,
we provide a unique model for the testing of novel therapeutic
drugs targeting CNNM2.
Materials and Methods
Ethics statement
All genetic studies were approved by the ethics committee of the
Westfa¨lische Wilhelms University, Mu¨nster. All patients or their
parents provided written informed consent in accordance to the
Declaration of Helsinki. All animal experiments were performed in
agreement with European, National and Institutional regulations.
Animal experimentation and analysis was restricted to the first five
days post-fertilization (dpf).
(P,0.05). (B) Representative immunoblots showing that p.Glu122Lys and p.Ser269Trp mutations reduce CNNM2 membrane expression (upper blot)
and a CNNM2 expression control (lower blot). Quantification of cell surface expression of wild-type (WT) and mutant CNNM2 proteins corrected for
total protein expression. Results are the mean 6 SEM of 3 independent experiments. * indicate significant differences compared to WT CNNM2
transfected cells (P,0.05).
doi:10.1371/journal.pgen.1004267.g003
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Figure 4. Knockdown of cnnm2a results in Mg wasting in zebrafish larvae (5 dpf). (A) mRNA expression of cnnm2a in developing zebrafish.
Expression patterns were analysed by RT-qPCR (n = 6 per time point). (B) Survival curve at 5 dpf (n = 3 per experimental condition). The dose of zero
represents injection with control-MO. (C) Morphological phenotypes in zebrafish larvae (5 dpf) in cnnm2a knockdown experiments. (D) Distribution of
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Patients
We studied a cohort of six patients from five families with
hypomagnesemia and mental retardation. Patients F1.1 to F4.1 are
followed in secondary or tertiary care neuropediatric centres.
Neuroimaging was performed in F1.1, F2.1, F3.1, and F4.1 by
cranial MRI (magnetic resonance imaging). Psychological diagnostic
evaluation in patients F2.1 and F3.1 was performed using Snijders
Oomen Non-Verbal (SON) Intelligence Test (revised) 5.5–17 years.
Copy number variations (CNVs) associated with neurodevelopmental
delay and intellectual disability were excluded in patients F1.1 and
F2.1 by array CGH (comparative genomic hybridization) using the
Sureprint G3 Human CGH Microarray kit (Agilent Technologies,
Boeblingen, Germany) in patient F1.1 and using the Affymetrix
Cytogenetics Whole-Genome 2.7 Array in patient F2.1.
Homozygosity mapping and CNNM2 mutational analysis
Genomic DNA of affected individuals and available family
members was extracted from whole blood using standard methods.
A genome scan for shared homozygous regions was performed in
the two affected children F1.1 and F1.2 with suspected parental
consanguinity. Samples were genotyped on an Illumina human
660W Quad beadchip SNP array (Illumina, Eindhoven, The
Netherlands). Merlin 1.1.2 (University of Michigan, Ann Arbor,
MI, USA) was used to determine homozygous regions by linkage
analysis. As exact information on pedigree structure was missing,
we used a 1.7 Mb threshold for regions identical by descent that is
very rarely crossed by non-consanguineous samples, but allows to
identify most of the true homozygosity regions if parental
consanguinity is present [38]. A list of candidate genes within
the identified homozygous intervals was generated including
known Refseq genes as well as novel transcripts using Ensembl
Genome assembly GRCh37 via biomart (www.ensembl.org). At a
cut-off size of .1.7 Mb, eleven critical intervals were yielded on
autosomes with a cumulative size of 62 Mb. The gene list
generated from these loci included 322 RefSeq genes and putative
transcripts, including CNNM2 in a critical interval of 7.1 Mb on
chromosome 10. The entire coding region and splice-sites of the
most promising candidate gene CNNM2 were sequenced from
both strands (Genbank: NM_017649.4, Uniprot: Q9H8M5). After
discovery of a homozygous mutation in the index family F1, the
mutational screening was extended to patients with hypomagne-
semia without mutations in known genes involved in hereditary
magnesium wasting. The presence of newly identified CNNM2
sequence variations was tested in at least 204 ethnically matched
control alleles and compared to publically available exome data
(www.1000genomes.org; evs.gs.washington.edu). Additionally, all
identified mutations were ranked for potential damage on protein
function using Polyphen-2 (genetics.bwh.harvard.edu/cgi-bin/
ggi/ggi2.cgi).
DNA constructs
Mouse wild-type Cnnm2 construct was cloned into the pCINeo
HA IRES GFP vector as described previously [12]. Cnnm2
mutations were inserted in the construct using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA)
according to the manufacturer’s protocol. All constructs were
verified by sequence analysis. Primer sequences used for cloning or
mutagenesis PCR are reported in Table S1.
Cell culture
HEK293 cells were grown in Dulbecco’s modified eagle’s
medium (DMEM, Bio Whittaker-Europe, Verviers, Belgium)
containing 10% (v/v) fetal calf serum (PAA, Liz, Austria), 2 mM
L-glutamine and 10 mg/mL non-essential amino acids, at 37uC in
a humidity-controlled incubator with 5% (v/v) CO2. The cells
were transiently transfected with the respective DNA constructs
using Lipofectamin 2000 (Invitrogen, Breda, The Netherlands) at
1:2 DNA:Lipofectamin ratio for 48 hours unless otherwise stated.
Cell surface biotinylation
HEK293 cells were transfected with wild-type and mutant
CNNM2 constructs for 48 hours. Subsequently, cell surface
proteins were biotinylated as described previously [39]. Briefly,
cell surface proteins were biotinylated for 30 min at 4uC in
0.5 mg/mL sulfo-NHS-LC-LC-biotin (Pierce, Rockford, IL,
USA). Cells were washed and lysed in lysis buffer (150 mM NaCl,
5 mM EGTA, Triton 1% (v/v), 1 mg/ml pepstatin, 1 mM PMSF,
5 mg/ml leupeptin, 5 mg/ml aproptin, 50 mM Tris/HCl, pH 7.5).
10% (v/v) of the sample was taken as input control and the rest of
the protein lysates were incubated overnight with NeutrAvidin-
agarose beads (Pierce, Rockford, IL, USA) at 4uC. The next day,
unbound protein was discarded by washing the beads 5 times with
lysis buffer. The remaining protein lysates were denatured in
Laemmli containing 100 mM DTT for 30 min at 37uC and
subsequently subjected to SDS-PAGE. Then, immunoblots were
incubated with mouse anti-HA 1:5,000 primary antibodies (Cell
Signaling Technology, Danvers, MA, USA) and peroxidase
conjugated sheep anti-mouse secondary antibodies 1:10,000
(Jackson Immunoresearch, Suffolk, UK).
Magnesium transport assays
HEK293 cells were transfected with wild-type and mutant
CNNM2 constructs for 48 hours and seeded on poly-L-lysine
(Sigma, St Louis, MO, USA) coated 12-well plates. Mg2+ uptake
was determined using a stable 25Mg2+ isotope (Cortecnet, Voisins
Le Bretonneux, France), which has a natural abundance of610%.
Cells were washed with basic uptake buffer (125 mM NaCl, 5 mM
KCl, 0.5 mM CaCl2, 0.5 mM Na2HPO4, 0.5 mM Na2SO4,
15 mM HEPES/NaOH, pH 7.5) and subsequently placed in
basic uptake buffer containing 1 mM 25Mg2+ (purity 698%) for
5 minutes unless stated differently. After washing three times with
ice-cold PBS, the cells were lysed in HNO3 ($65%, Sigma) and
subjected to ICP-MS (inductively coupled plasma mass spectrom-
etry) analysis. For extrusion experiments, cells were transfected
with wild-type or mutant CNNM2 constructs for 24 hours. After
24 hours, cells were placed in culture medium containing 1 mM
morphological phenotypes in zebrafish larvae (5 dpf) untreated (wild-type) or injected with different doses of cnnm2a-MO or control-MO. Numbers
on top of the bars indicate the number of animals in each experimental condition. (E) Distribution of morphological phenotypes in zebrafish larvae at
5 dpf in rescue experiments. The wild-type phenotype (class I) was restored in morphants by co-injection of cnnm2a-MO (2 ng MO/embryo) with
wild-type (WT) CNNM2 cRNA (50 pg cRNA/embryo), but not with mutant (MT, p.Glu357Lys) CNNM2 cRNA (50 pg cRNA/embryo). (F) Magnesium
content in zebrafish injected with different doses of cnnm2a-MO, the dose of zero represents injection with control-MO (n= 10 per experimental
condition except in 8 ng MO-injected zebrafish where n = 5). (G) Rescue of Mg wasting in morphant zebrafish by co-injection of cnnm2a-MO (2 ng
MO/embryo) with cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo). Co-injection with cRNA encoding for mutant (MT, p.Glu357Lys)
CNNM2 (50 pg cRNA/embryo) did not restore Mg levels (n = 10 per experimental condition). Data are presented as mean 6 SEM. Different letters
indicate significant differences between mean values in experimental groups (P,0.05).
doi:10.1371/journal.pgen.1004267.g004
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25Mg2+ (purity 698%) for an additional 48 hours. Before the start
of the experiment, the cells were briefly washed in basic uptake
buffer and subsequently placed in basic uptake buffer containing
0.5 mM Mg2+ (containing 610% 25Mg2+) for 5 minutes. After
washing three times with ice-cold PBS, the cells were lysed in nitric
acid and subjected to ICP-MS analysis.
Morpholino knockdown and rescue experiments
Wild-type Tupfel long-fin zebrafish were bred and raised under
standard conditions (28.5uC and 14 h of light: 10 h of dark cycle)
in accordance with international and institutional guidelines.
Zebrafish eggs were obtained from natural spawning. The
following antisense oligonucleotides (MOs) were raised against
the translational start site of cnnm2a and cnnm2b, along with the
standard mismatch control MO (Gene Tools, Philomath, OR,
USA): cnnm2a, 59-GCGGTCCATTGCTCTGCCATGTTGA-39;
cnnm2b, 59-ACCGACGGTTCTGCCATGTTGATAA-39; and
the negative control (standard mismatch MO), directed against a
human b-globin intron mutation, 59-CCTCTTACCTCAGTTA-
CAATTTATA. The underlined areas indicate the complementa-
ry sequences to the initial methionines of cnnm2a and cnnm2b. MOs
were diluted in deionized, sterile water supplemented with 0.5%
(w/v) phenol red and injected in a volume of 1 nl into the yolk of
one- to two-cell stage embryos using a Pneumatic PicoPump
pv280 (World Precision Instruments, Sarasota, FL, USA). Wild-
type (uninjected) embryos were also included in the experiments to
control for the effects of the injection procedure per se. To
determine the most effective dose of the cnnm2a- and cnnm2b-MO,
2, 4 and 8 ng were injected. In these experiments, control embryos
were injected with 8 ng of the standard mismatch control MO (the
highest dose). After injection, embryos from the same experimental
condition were placed in 3 Petri dishes (at a maximum density of
45 embryos/dish, allowing statistical comparisons between surviv-
als in the different experimental conditions) and cultured at 28.5uC
in E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM
CaCl2, 0.33 mM MgSO4), which was refreshed daily. As criteria
for subsequent experiments, the dose of MO that caused major
effects and induced a percentage of mortality non-significantly
different from controls was injected (2 ng for cnnm2a-MO and 8 ng
for cnnm2b-MO). In experiments that implied exposure to high
Mg2+ concentrations, the high Mg2+ medium had a composition of
5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2 and 25 mM
MgSO4. In order to control for the specificity of the MOs
blocking the translation of cnnm2a and cnnm2b, as well as for toxic
off-target effects, in vivo cRNA rescue experiments were performed
[40]. For these experiments, mouse wild-type CNNM2 and
mutant (p.Glu357Lys) CNNM2 cRNAs were prepared using the
mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA)
according to the manufacturer’s instructions. The cRNAs, in an
amount of 50 pg, as based on other studies [26], were (co)injected
together with MOs as described above. Zebrafish embryos and
larvae were phenotyped at 25 hpf or 5 dpf, respectively.
Analysis of phenotypes in embryos and larvae
For the analyses of brain phenotypes, the brain rudiment of
zebrafish embryos at 25 hpf was observed for morphological
changes under a Leica MZFLIII microscope (Leica Microsystems
Ltd, Heerburgg, Germany). Morphological phenotypes, which
also included the brain, were also analysed in larvae at 5 dpf.
Embryos or larvae were classified into different classes of
phenotypes on the basis of comparisons with stage-matched
control embryos of the same clutch. In cnnm2a morphant embryos
(25 hpf), two phenotype classes were distinguished: class I, normal;
and class II, embryos with underdeveloped MHB. In cnnm2a
morphant larvae (5 dpf), the following classes were distinguished:
class I, normal; class II, normal with non-inflated swim bladder;
class III, larvae with enlarged pericardial cavity (edema) and non-
inflated swim bladder; class IV, larvae with notochord defects,
enlarged pericardial cavity and non-inflated swim bladder; and
class V, larvae with severely enlarged pericardial cavity, notochord
defects and non-inflated swim bladder. In cnnm2b morphant
embryos (25 hpf), three different phenotypes were distinguished:
class I, normal; class II, embryos with underdeveloped MHB; and
class III, embryos with underdeveloped MHB and enlarged
tectum. In cnnm2b morphant larvae (5 dpf), the number of different
phenotypes distinguished were four: class I, normal; class II,
normal with non-inflated swim bladder; class III, larvae with
enlarged pericardial cavity (edema) and non-inflated swim
bladder; and class IV, larvae with widened outer cerebrospinal
fluid spaces, kidney cysts, severely enlarged pericardial cavity and
non-inflated swim bladder. Representative images were obtained
with a DFC450C camera (Leica Microsystems Ltd) after
anaesthetising embryos or larvae with tricaine/Tris pH 7.0
solution. Prior to anaesthesia and image acquisition, zebrafish
embryos were manually dechorionated.
Magnesium determinations in embryos and larvae
Zebrafish embryos or larvae were anesthetized with tricaine/
Tris pH 7.0 solution and 5–7 individuals were pooled as one
sample. Samples were then snap frozen in liquid nitrogen and
stored at 280uC in order to ensure euthanasia of animals and
remained at these storage conditions until the beginning of the
analytical procedures.
Analytical procedures started by quickly washing the samples
with nanopure water in order to avoid contamination of remaining
waterborne Mg2+. The washing procedure was repeated twice.
Fish were then dried at 65uC for 1.5 hours, at which time 2.5 ml of
HNO3 ($65%, Sigma) was added to each tube. Samples were
digested at 65uC during 1.5 hours. After, digested samples were
diluted 1:10 with 22.5 ml nanopure water. The total Mg content in
Figure 5. Knockdown of cnnm2b results in Mg wasting and brain malformations in zebrafish larvae (5 dpf). (A) mRNA expression of
cnnm2b in developing zebrafish. Expression patterns were analysed by RT-qPCR (n = 6 per time point). (B) Survival curve at 5 dpf (n = 3 per
experimental condition). The dose of zero represents injection with control-MO. (C) Morphological phenotypes in zebrafish larvae (5 dpf) in cnnm2b
knockdown experiments. (D) Distribution of morphological phenotypes in zebrafish larvae (5 dpf) untreated (wild-type) or injected with different
doses of cnnm2b-MO or control-MO. Brain malformations (widened cerebrospinal fluid spaces, class IV phenotype) are prominent in morphants
injected with 4–8 ng MO/embryo. Numbers on top of the bars indicate the number of animals in each experimental condition. (E) Distribution of
morphological phenotypes in zebrafish larvae at 5 dpf in rescue experiments. The wild-type phenotype (class I) was restored in morphants by co-
injection of cnnm2b-MO (8 ng MO/embryo) with wild-type (WT) CNNM2 cRNA (50 pg cRNA/embryo), but not with mutant (MT, p.Glu357Lys) CNNM2
cRNA (50 pg cRNA/embryo). (F) Magnesium content in zebrafish injected with different doses of cnnm2b-MO. The dose of zero represents injection
with control-MO (n= 10 per experimental condition). (G) Rescue of Mg wasting in morphant zebrafish by co-injection of cnnm2b-MO (8 ng MO/
embryo) with cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo). Co-injection with cRNA encoding for mutant (MT, p.Glu357Lys)
CNNM2 (50 pg cRNA/embryo) did not restore Mg levels (n = 10 per experimental condition). Data are presented as mean 6 SEM. Different letters
indicate significant differences between mean values in experimental groups (P,0.05).
doi:10.1371/journal.pgen.1004267.g005
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Figure 6. Dysfunctional cnnm2a causes brain abnormalities and increased spontaneous contractions in zebrafish embryos (25 hpf).
(A) Phenotypes in zebrafish embryos untreated (wild-type) or following treatment with cnnm2a-MO (2 ng MO/embryo) or control-MO. Abbreviations
indicate the following parts in the zebrafish embryonic brain: M, midbrain; T, tectum; MHB, midbrain-hindbrain boundary; FV, fourth ventricle; and H,
hindbrain. (B) Distribution of phenotypes and (C) Mg content (n = 10 per experimental condition) in zebrafish embryos untreated (wild-type) or
injected with 2 ng of cnnm2a-MO or control-MO and exposed to a medium with a concentration of Mg2+ of 0.33 or 25 mM. Numbers on top of the
bars indicate the number of animals in each experimental condition. (D) Restoration of normal brain development by co-injection of cnnm2a-MO
(2 ng MO/embryo) with cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo), and not by co-injection with cRNA encoding for mutant
(MT, p.Glu357Lys) CNNM2 (50 pg cRNA/embryo). (E) Spontaneous contractions in zebrafish embryos untreated (wild-type) or injected with 2 ng of
cnnm2a-MO or control-MO and exposed to a medium with a concentration of Mg2+ of 0.33 or 25 mM (n= 30 per experimental condition). (F)
Restoration of normal spontaneous contraction activity (n = 30 per experimental condition) by co-injection of cnnm2a-MO (2 ng MO/embryo) with
cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo), and not by co-injection with cRNA encoding for mutant (MT, p.Glu357Lys) CNNM2
(50 pg cRNA/embryo). Data are presented as mean 6 SEM. *P,0.05 versus wild-type and control. #P,0.05 versus Mg2+-normal (0.33 mM Mg2+)
medium. Data are presented as mean6 SEM. Different letters indicate significant differences between mean values in experimental groups (P,0.05).
doi:10.1371/journal.pgen.1004267.g006
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Figure 7. Dysfunctional cnnm2b causes brain abnormalities and increased spontaneous contractions in zebrafish embryos (25 hpf).
(A) Phenotypes in zebrafish embryos untreated (wild-type) or following treatment with cnnm2b-MO (8 ng MO/embryo) or control-MO. See Figure 6
for an explanation of the abbreviations shown. (B) Distribution of phenotypes and (C) Mg content (n = 10 per experimental condition) in zebrafish
embryos untreated (wild-type) or injected with 8 ng of cnnm2b-MO or control-MO and exposed to a medium with a concentration of Mg2+ of 0.33 or
25 mM. Numbers on top of the bars indicate the number of animals in each experimental condition. (D) Restoration of normal brain development by
co-injection of cnnm2b-MO (8 ng MO/embryo) with cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo), and not by co-injection with
cRNA encoding for mutant (MT, p.Glu357Lys) CNNM2 (50 pg cRNA/embryo). (E) Spontaneous contractions in zebrafish embryos untreated (wild-type)
or injected with 8 ng of cnnm2b-MO or control-MO and exposed to a medium with a concentration of Mg2+ of 0.33 or 25 mM (n = 30 per
experimental condition). (F) Restoration of normal spontaneous contraction activity (n = 30 per experimental condition) by co-injection of cnnm2b-
MO (8 ng MO/embryo) with cRNA encoding for wild-type (WT) CNNM2 (50 pg cRNA/embryo), and not by co-injection with cRNA encoding for
mutant (MT, p.Glu357Lys) CNNM2 (50 pg cRNA/embryo). Data are presented as mean 6 SEM. *P,0.05 versus wild-type and control. #P,0.05 versus
Mg2+-normal (0.33 Mm Mg2+) medium. Data are presented as mean 6 SEM. Different letters indicate significant differences between mean values in
experimental groups (P,0.05).
doi:10.1371/journal.pgen.1004267.g007
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each sample was determined with a commercial colorimetric assay
(Roche Diagnostics, Woerden, The Netherlands) following the
manufacturer’s protocol. Blanks (HNO3 diluted 1:10 with
nanopure water) were added during assays and values were equal
to zero. Within-run precision and accuracy was controlled by
means of an internal control Precinorm (Roche Diagnostics).
Samples from embryos exposed to 25 mM Mg2+ were further
diluted (1:20). Furthermore, samples were normalized by protein
content, which was determined in 1:20 (embryos at 25 hpf) or 1:50
(larvae at 5 dpf) diluted samples using the Pierce BCA protein
assay kit (Pierce Biotechnology, Rockford, IL, USA).
Total RNA isolation, cDNA synthesis and quantitative
real-time PCR analysis
Zebrafish embryos or larvae at specific developmental times (6,
12, 24, 48, 72, 96 and 120 hpf) were anaesthetised with tricaine/
Tris pH 7 solution and 10 individuals were pooled as one sample.
RNA isolation, cDNA synthesis and quantitative real-time PCR
(RT-qPCR) measurements were carried out as previously
described using validated cnnm2a and cnnm2b primers [18].
Samples were normalized to the expression level of the house-
keeping gene elongation factor-1a (elf1a) [18]. Relative mRNA
expression was analysed using the Livak method (22DDCt), where
results are expressed relative to the gene expression at 6 hpf (time
point chosen as calibrator).
Spontaneous contraction analysis and touch-evoked
escape behaviour
At 25 hpf, 10 zebrafish embryos per Petri dish (n = 30 per
experimental condition) were randomly selected. The number of
complete body contractions each zebrafish made in 30 second
period was counted and was used as indicative of motor neuron
activity [27]. Representative videos of each experimental condition
were taken using Leica Application Suite (Leica Microsystems Ltd)
and a Leica MZFLIII microscope (Leica Microsystems Ltd)
equipped with a DFC450C camera (Leica Microsystems Ltd).
For the analysis of the touch-evoked escape behaviour, 10
zebrafish larvae per Petri dish (n = 30 per experimental condition)
were randomly selected. Touch-evoked escape behaviours were
elicited by touching a larva in the tail up to 6 times with a pair of
forceps at 5 dpf. Three categories were distinguished, responders,
late responders and non-responders, to which the following scores
were given: 3 points for responders: fish quickly react (swimming
or flicking the tail) to the stimuli after 1 or 2 twitches; 2 points for
late responders: fish react (swimming or flicking the tail) to the
stimuli after 3, 4 or 5 twitches; and 1 point for non-responders: fish
do not react to the stimuli after more than 5 twitches. Represen-
tative videos were recorded with the system described above.
Statistical analysis
All results are depicted as mean 6 standard error of the mean
(SEM). Statistical analyses were conducted by one- or two-way (for
experiments where zebrafish embryos were exposed to different
Mg2+ concentrations, then two factors of variance appear: Mg2+
concentration and treatment) ANOVA. Where appropriate, data
were logarithmically transformed to fulfil the requirements for
ANOVA, but all data are shown in their decimal values for clarity.
When data did not comply with the premises of the parametric
ANOVA, data were analyzed using a Kruskal-Wallis ANOVA on
ranks. Tukey’s post-test was used to identify significantly different
groups. Statistical significance was accepted at P,0.05.
Supporting Information
Figure S1 Impairment of touch-evoked escape behaviour in
cnnm2a morphant zebrafish. Touch-evoked escape behaviour score
in zebrafish cnnm2a morphants at 5 dpf after injection of 2 ng
control-MO/embryo, 2 ng cnnm2a-MO/embryo, 2 ng cnnm2a-
MO/embryo+50 pg wild-type (WT) CNNM2 cRNA/embryo, or
2 ng cnnm2a-MO/embryo+50 pg mutant (MT, p.Glu357Lys)
CNNM2 cRNA/embryo. Three categories were distinguished,
responders, late responders and non-responders, to which the
following scores were given: 3 points for responders: fish quickly
react (swimming or flicking the tail) to the stimuli after 1 or 2
twitches; 2 points for late responders: fish react (swimming or
flicking the tail) to the stimuli after 3, 4 or 5 twitches; and 1 point
for non-responders: fish do not react to the stimuli after more than
5 twitches. The upper part of the figure shows frames of videos
showing touch-evoked escape contractions at 5 dpf of control and
morphant zebrafish larvae. Time of each video frame is indicated
in centisenconds (cs). Data are shown as mean 6 SEM (n= 30).
Different letters indicate significant differences between mean
values in experimental groups (P,0.05).
(TIF)
Figure S2 Impairment of touch-evoked escape behaviour in
cnnm2b morphant zebrafish. Touch-evoked escape behaviour score
in zebrafish cnnm2b morphants at 5 dpf after injection of 8 ng
control-MO/embryo, 8 ng cnnm2b-MO/embryo, 8 ng cnnm2b-
MO/embryo+50 pg wild-type (WT) CNNM2 cRNA/embryo, or
2 ng cnnm2b-MO/embryo+50 pg mutant (MT, p.Glu357Lys)
CNNM2 cRNA/embryo. Three categories were distinguished,
responders, late responders and non-responders, to which the
following scores were given: 3 points for responders: fish quickly
react (swimming or flicking the tail) to the stimuli after 1 or 2
twitches; 2 points for late responders: fish react (swimming or
flicking the tail) to the stimuli after 3, 4 or 5 twitches; and 1 point
for non-responders: fish do not react to the stimuli after more than
5 twitches. The upper part of the figure shows frames of videos
showing touch-evoked escape contractions at 5 dpf of control and
morphant zebrafish larvae. Time of each video frame is indicated
in centisenconds (cs). Data are shown as mean 6 SEM (n= 30).
Different letters indicate significant differences between mean
values in experimental groups (P,0.05).
(TIF)
Movie S1 Spontaneous contraction frequency in zebrafish
embryos (25 hpf) injected with a dose of 2 ng control-MO/
embryo.
(AVI)
Movie S2 Spontaneous contraction frequency in zebrafish
embryos (25 hpf) injected with a dose of 2 ng cnnm2a-MO/
embryo.
(AVI)
Movie S3 Spontaneous contraction frequency in zebrafish
embryos (25 hpf) co-injected with a dose of 2 ng cnnm2a-MO/
embryo and 50 pg of mutant (p.Glu357Lys) CNNM2 cRNA.
(AVI)
Movie S4 Spontaneous contraction frequency in zebrafish
embryos (25 hpf) injected with a dose of 8 ng control-MO/
embryo.
(AVI)
Movie S5 Spontaneous contraction frequency in zebrafish
embryos (25 hpf) injected with a dose of 8 ng cnnm2b-MO/
embryo.
(AVI)
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Movie S6 Spontaneous contraction frequency in zebrafish
embryos (25 hpf) co-injected with a dose of 8 ng cnnm2b-MO/
embryo and 50 pg of mutant (p.Glu357Lys) CNNM2 cRNA.
(AVI)
Table S1 Primer sequences for mutagenesis PCR.
(DOCX)
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